Data / Research funding / Wisconsin / Versiti Blood Health, Inc.
Versiti Blood Health, Inc.: 51 NIH awards ($87.9M), fiscal years 2021 to 2026
Versiti Blood Health, Inc. in Milwaukee, WI is funded under 51 NIH awards ($87.9M) in the NIH and NSF award files, read 2026-11-04. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- JZDRNT166LE4
- State
- Wisconsin
Awards
51 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Molecular and Clinical Glycobiology of the Bone Marrow Environment | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $12,294,902 | January 1, 2021 | December 31, 2026 | HOFFMEISTER, KARIN MARIA | reporter.nih.gov |
| Zimmerman Program on the Biology of VWD | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $7,898,432 | March 15, 2019 | February 28, 2025 | MONTGOMERY, ROBERT R | reporter.nih.gov |
| Molecular Mechanisms of Immune Thrombocytopenia in Transfusion Medicine | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $5,130,743 | August 1, 2024 | July 31, 2029 | NEWMAN, PETER J | reporter.nih.gov |
| REDS-IV-P DOMESTIC HUBS | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $4,838,246 | July 1, 2024 | June 30, 2026 | MAST, ALAN E | reporter.nih.gov |
| Basic Investigation and Translational Applications Concerning the Cell and Molecular Biology of Blood and Vascular Cells | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,926,545 | March 1, 2018 | February 28, 2026 | NEWMAN, PETER J | reporter.nih.gov |
| Characterization of an isoform specific anticoagulant function of TFPI-alpha | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,004,684 | August 1, 2002 | June 30, 2028 | MAST, ALAN E | reporter.nih.gov |
| Endothelial Rap1 in the control of heart function | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,940,444 | January 19, 2022 | December 31, 2026 | CHRZANOWSKA, MAGDALENA | reporter.nih.gov |
| TFPI, Protein S, and Plasma FIXa in Hormone-Induced Hypercoagulability | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,796,684 | August 1, 2021 | July 31, 2025 | MAST, ALAN E | reporter.nih.gov |
| Development of a B Cell Therapeutic | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,713,112 | August 20, 2020 | July 31, 2025 | DITTEL, BONNIE N | reporter.nih.gov |
| B-cell response and thrombotic complications in COVID-19 | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,626,288 | February 1, 2022 | January 31, 2027 | WEN, RENREN | reporter.nih.gov |
| B cell responses in heparin-induced thrombocytopenia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,568,465 | January 1, 2017 | June 30, 2026 | WANG, DEMIN | reporter.nih.gov |
| Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2024 | $2,518,197 | July 1, 2020 | June 30, 2025 | DEININGER, MICHAEL W. | reporter.nih.gov |
| Structural Transition of Cellular Integrins and Applications Thereof | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,480,610 | September 1, 2016 | November 30, 2028 | ZHU, JIEQING | reporter.nih.gov |
| Understanding and Controlling the Contribution of Fibrinolysis to Bleeding Using a Long-Acting Antifibrinolytic RNA Therapy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,182,730 | August 15, 2023 | July 31, 2027 | KASTRUP, CHRISTIAN | reporter.nih.gov |
| Pulmonary arteriole occlusion by platelet-neutrophil micro-emboli in Acute Chest Syndrome | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $2,061,301 | August 15, 2015 | June 30, 2027 | SUNDD, PRITHU | reporter.nih.gov |
| Glycans in Blood Homeostasis and Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,944,000 | July 1, 2018 | June 30, 2024 | HOFFMEISTER, KARIN MARIA | reporter.nih.gov |
| Molecular Basis of the Humoral Immune Response in Heparin-Induced Thrombocytopenia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $1,893,899 | June 1, 2019 | April 30, 2029 | WEN, RENREN | reporter.nih.gov |
| Kindlin-3 signaling in neutrophils | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,801,567 | March 1, 2022 | January 31, 2026 | MA, YAN-QING | reporter.nih.gov |
| Carbohydrate-Mediated Platelet Clearance | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,755,671 | February 1, 2023 | January 31, 2027 | HOFFMEISTER, KARIN MARIA | reporter.nih.gov |
| Kindlin-3 signaling in platelets | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $1,742,425 | February 10, 2022 | January 31, 2026 | MA, YAN-QING | reporter.nih.gov |
| CD39-carrying extracellular vesicles regulate pulmonary thrombosis in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,552,984 | August 1, 2023 | July 31, 2027 | SUNDD, PRITHU | reporter.nih.gov |
| The function of MS4A3 in normal and malignant hematopoiesis | NIH | National Cancer Institute | 2023 to 2025 | $1,532,077 | January 1, 2023 | December 31, 2027 | DEININGER, MICHAEL W. | reporter.nih.gov |
| Strategies to target BCR-ABL1 compound mutants in CML and Ph+ ALL | NIH | National Cancer Institute | 2022 to 2025 | $1,475,782 | November 10, 2021 | June 30, 2026 | DEININGER, MICHAEL W. | reporter.nih.gov |
| Non-conventional signaling by α5 integrin in blood and endothelial cells | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,437,708 | July 15, 2024 | June 30, 2028 | ZHU, JIEQING | reporter.nih.gov |
| Endothelial Rap1 restricts inflammation in the retina | NIH | National Eye Institute | 2024 to 2025 | $1,173,571 | September 30, 2024 | August 31, 2029 | CHRZANOWSKA, MAGDALENA | reporter.nih.gov |
| The histone demethylase JMJD1C in human Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2023 | $1,135,709 | May 16, 2019 | April 30, 2024 | ZHU, NAN | reporter.nih.gov |
| Structural Mechanisms Underlying the Activity Regulation of the Receptor-like Protein Tyrosine Phosphatase, CD148/PTPRJ | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,080,500 | May 1, 2020 | April 30, 2025 | ZHU, JIEQING | reporter.nih.gov |
| Interrogating clinically relevant attributes of maternal alloimmunity in fetal/neonatal alloimmune thrombocytopenia | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $935,260 | May 1, 2024 | April 30, 2028 | NEWMAN, DEBRA KAY | reporter.nih.gov |
| Phenotypic, Functional and Transcriptional Heterogeneity in T Cell Exhaustion | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $914,926 | December 16, 2019 | August 26, 2022 | CUI, WEIGUO | reporter.nih.gov |
| Investigating the regulation and substrate processing of ADAMTS13 and ADAMTS7 metalloproteases | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $825,000 | August 1, 2021 | May 31, 2026 | MUIA, JOSHUA MUTAMBUKI | reporter.nih.gov |
| High parameter fluorescence activated cell sorter | NIH | Office of the Director, National Institutes of Health | 2025 | $679,925 | July 15, 2025 | July 14, 2026 | HOFFMEISTER, KARIN MARIA | reporter.nih.gov |
| The role in inflammation in platelet activation and thrombosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $648,172 | January 8, 2020 | December 31, 2024 | BRANCHFORD, BRIAN R | reporter.nih.gov |
| A Bioluminescent Assay for Direct Measurement of Sirtuin Activity in Cancer Cells | NIH | National Cancer Institute | 2021 to 2022 | $605,594 | September 10, 2021 | August 31, 2025 | DEININGER, MICHAEL W. | reporter.nih.gov |
| Membrane-cytoskeleton interactions in megakaryocytes and platelets | NIH | National Heart, Lung, and Blood Institute | 2025 | $604,301 | August 1, 2025 | April 30, 2029 | FALET, HERVE | reporter.nih.gov |
| Molecular Interactions of FVIII and VWF | NIH | National Heart, Lung, and Blood Institute | 2021 | $586,287 | February 15, 2018 | December 31, 2022 | MONTGOMERY, ROBERT R | reporter.nih.gov |
| Therapeutic targeting of an oncogenic translational program in AML | NIH | National Cancer Institute | 2025 | $545,170 | April 1, 2025 | March 31, 2030 | PULIKKAN, JOHN | reporter.nih.gov |
| The cellular mechanisms of immunological memory development in COVID-19 patients | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $428,542 | September 1, 2021 | August 26, 2022 | CUI, WEIGUO | reporter.nih.gov |
| VWF - Mechanisms of Regulation | NIH | National Heart, Lung, and Blood Institute | 2021 | $416,631 | August 15, 2018 | June 30, 2023 | HABERICHTER, SANDRA | reporter.nih.gov |
| Cohesin Mutations in Acute Myelogenous Leukemia | NIH | National Cancer Institute | 2021 | $376,691 | September 19, 2017 | July 31, 2023 | RAO, SRIDHAR | reporter.nih.gov |
| Training in Transfusion Medicine and Classical Hematology | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $264,357 | May 1, 2024 | April 30, 2029 | MAST, ALAN E | reporter.nih.gov |
| DNA damage responses to genome editing in hematopoietic stem cells | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $242,048 | September 8, 2025 | August 31, 2027 | DOERFLER, PHILLIP A | reporter.nih.gov |
| Pre-mRNA Processing and Function of Alternatively Spliced Isoforms of TFPI | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $232,668 | April 15, 2023 | March 31, 2026 | SIEBERT-MCKENZIE, AMY | reporter.nih.gov |
| Molecular Mechanism of Sickle Cell Hepatic Crisis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $221,969 | July 15, 2020 | April 30, 2026 | PRADHAN-SUNDD, TIRTHADIPA | reporter.nih.gov |
| Cytokine regulation of recirculating and tissue-resident memory CD8+ T cells in homeostasis and inflammation | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $162,000 | August 12, 2025 | July 31, 2027 | JARJOUR, NICHOLAS N | reporter.nih.gov |
| Defining the mechanisms of hemoglobin switching and genotoxicities associated with its manipulation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $158,220 | September 21, 2024 | December 31, 2026 | DOERFLER, PHILLIP A | reporter.nih.gov |
| Mechanisms of Flow-driven Transcriptional Control of Hematopoietic Stem Cell Development by YAP | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $158,220 | July 1, 2021 | January 31, 2027 | SUGDEN, WADE WILLIAM | reporter.nih.gov |
| Reprogramming tumor-reactive CD8 T cells by targeting the IL-21-BATF pathway to treat melanoma | NIH | National Cancer Institute | 2021 to 2023 | $152,572 | January 1, 2020 | December 31, 2023 | TOPCHYAN, PAYTSAR | reporter.nih.gov |
| Defining the transcriptional, phenotypic, and functional heterogeneity of virus-specific CD4 T cells during chronic viral infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $112,127 | July 1, 2020 | June 30, 2022 | ZANDER, RYAN | reporter.nih.gov |
| Cohesin Mutations in Core-Binding Factor Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2022 | $102,788 | July 1, 2019 | June 30, 2023 | HEIMBRUCH, KATELYN E | reporter.nih.gov |
| Nuclear Architecture-driven Cellular Heterogeneity in Stem Cell and Hematopoietic Differentiation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $51,036 | September 5, 2018 | September 4, 2022 | AGRAWAL, PUJA | reporter.nih.gov |
| The Translational Glycomics Symposium | NIH | National Heart, Lung, and Blood Institute | 2024 | $11,286 | September 1, 2024 | August 31, 2025 | HOFFMEISTER, KARIN MARIA | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 26 | $18,503,684 | 0 | $0 |
| 2024 | 28 | $19,805,892 | 0 | $0 |
| 2023 | 22 | $15,065,516 | 0 | $0 |
| 2022 | 24 | $17,724,123 | 0 | $0 |
| 2021 | 25 | $16,843,851 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 2 awards here | |
| Emerging Global Leader Award (K43 Independent Clinical Trial Required) | PAR-24-295 | NIH | 93.839 | December 3, 2026 | Not listed | Same assistance listing 93.839 as 26 awards here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) | PAR-24-296 | NIH | 93.839 | December 3, 2026 | Not listed | Same assistance listing 93.839 as 26 awards here |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | NIH | 93.839 | December 4, 2026 | Not listed | Same assistance listing 93.839 as 26 awards here |
| Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional) | PAR-27-039 | NIH | 93.839 | January 5, 2027 | Not listed | Same assistance listing 93.839 as 26 awards here |
| Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional) | PAR-27-040 | NIH | 93.839 | January 5, 2027 | Not listed | Same assistance listing 93.839 as 26 awards here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.839 | January 7, 2027 | $375,000 | Same assistance listing 93.839 as 26 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.839 | January 7, 2027 | Not listed | Same assistance listing 93.839 as 26 awards here |
| NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required) | PAR-25-025 | NIH | 93.839 | February 3, 2027 | $1.5 million | Same assistance listing 93.839 as 26 awards here |
| NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required) | PAR-25-026 | NIH | 93.839 | February 3, 2027 | Not listed | Same assistance listing 93.839 as 26 awards here |
| Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required) | PAR-27-125 | NIH | 93.839 | February 16, 2027 | Not listed | Same assistance listing 93.839 as 26 awards here |
| Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed) | RFA-DK-27-108 | NIH | 93.839 | March 10, 2027 | $500,000 | Same assistance listing 93.839 as 26 awards here |
| NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional) | PAR-25-032 | NIH | 93.839 | March 16, 2027 | Not listed | Same assistance listing 93.839 as 26 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.839 | April 5, 2027 | Not listed | Same assistance listing 93.839 as 26 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.839 | April 5, 2027 | Not listed | Same assistance listing 93.839 as 26 awards here |
| Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25 Clinical Trials Not Allowed) | RFA-OD-25-003 | NIH | 93.839 | April 9, 2027 | $200,000 | Same assistance listing 93.839 as 26 awards here |
| NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional) | RFA-HL-26-002 | NIH | 93.839 | April 28, 2027 | Not listed | Same assistance listing 93.839 as 26 awards here |
| NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional) | RFA-HL-26-003 | NIH | 93.839 | April 28, 2027 | Not listed | Same assistance listing 93.839 as 26 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required) | PA-24-175 | NIH | 93.839 | May 7, 2027 | Not listed | Same assistance listing 93.839 as 26 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.839 | May 7, 2027 | Not listed | Same assistance listing 93.839 as 26 awards here |
Topics of its NIH awards
- Hematology
- Genetics
- Rare Diseases
- Clinical Research
- Pediatric
- Cancer
- Biotechnology
- Stem Cell Research
- Cardiovascular
- Orphan Drug
- Immunotherapy
- Infectious Diseases
Updated November 4, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-04). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.